Clinical Trial Search

Primary: The Proportion of Subjects Reporting at Least 50% Overall Pain Relief — 19; 14; 10; 16 Participants — p=.196

Primary: Change From Baseline in the Average Pain Intensity Score at Week 12 — 6.13; 6.04; 6.05; -1.42 Score on a scale

Primary: Change From Baseline to Days 24-28 in Numerical Rating Scale (NRS) Average Pain Score. — -1.53; -1.54; -1.44 Scores on a scale

Primary: Blood Oxygenation Level-dependent (BOLD) Changes in Neural Pain Circuitry Following Treatment With Lamotrigine During Experimentally Induced Pain States — -2.9294…

Primary: Mean Pain Score on Daily Pain Rating Scale (DPRS) — 4.32; 4.22; 5.57 units on a scale — p=0.3910

Primary: Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score — -2.12; -1.63 Scores on a scale — p=0.0125

Primary: Primary Endpoint Will be the Change From Baseline in Average Pain Score Over the Last 7 Days of the Maintenance Phase. — -2.65; -2.22 Scores on a scale — p=0.2537

Primary: Change From Baseline in Average Daily Pain Numeric Rating Scale (NRS) Score at Week 6 — 6.40; 6.42; 6.39; -1.22 units on a scale — p=0.687

Primary: Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data…

Primary: Change in Pain Score — -0.6224; -1.005; -0.8102; -1.079 score on a scale

Primary: Daily Evening Patient Reported Pain Intensity Scores — 0.14; 1.57 Units on a Scale — p=0.003

Primary: Time to Return to Baseline Pain After Injection. — 8; 5 hours — p=0.374

Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001

Primary: Mean Pain Scores at Endpoint — 5.12; 4.81; 4.26; 4.49 score on scale — p=0.262

Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018

Primary: Number of Participants With Loss of Therapeutic Response. — 29; 63 Participants — p=<0.0001

Primary: Change in Mean Pain (NRPS) From Baseline to Endpoint in Mean Pain — -1.9447; -1.9786; -1.6798; -1.6633 Points

Primary: Average Number of Pain Attacks — 3.3533; 3.1807 Pain attacks

Primary: Change From Baseline to End of Study in LOCF VAS — -20.4; -21.3 scores on a scale

Primary: Baseline Mean Pain Score — 5.93; 6.08 units on a scale

Primary: Summary of Adverse Events — 124; 14; 5; 17 subjects

Primary: Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the Last Week of Each Treatment Period Using Last Observation Carried Forward (LOCF) Data…

Primary: Baseline Mean Pain Score — 6.41; 6.54 units on a scale

Primary: Change in Pain Scores Comparing NP-1 Cream vs. Placebo Cream for Treatment of the Pain of Post Herpetic Neuralgia(PHN)From Baseline to 28 Days. — 2.424; 2.471; 1.877…

Primary: Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60 — .1; .1 nerve fibers / mm squared

Primary: Mean Neuropathic Pain Score at Visit 3 (Week 1) — 51.00; 50.70 Units on a Scale

Primary: Percentage Change in Average Pain Intensity Score From Baseline to the Last Week of the 4-week Treatment Period — -26.16; -26.11; -27.36 percentage of change — p==0.965

Primary: Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline — -2.88; -2.63 score on scale…

Primary: Change From Baseline in Average Pain Scores to Week 15/ End of Treatment (EOT) (Including Modified BOCF Data) — -0.55; -1.30; -0.95; -0.50 Scores on a scale

Primary: Change From Baseline in Average Numerical Rating Scale (NRS) Score at Week 12 — 6.7; 6.9; -2.6; -2.6 Units on a scale